Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
JCP Capital (境成资本) is a venture capital firm established in 2017 and headquartered in Shenzhen, China. The firm focuses on investing in deep technologies and health-tech companies, emphasizing the industrialization of innovative solutions. JCP Capital leverages its team's extensive experience in entrepreneurship and international investment to identify and support startups with high growth potential.
As of now, JCP Capital manages a fund size of approximately $500 million, targeting early to growth-stage investments. The firm has a portfolio of 10 companies and is known for its strategic capital and value-added services. JCP Capital's management team has backgrounds in capital management from Silicon Valley and the Guangdong-Hong Kong-Macao Greater Bay Area, enhancing their ability to identify promising startups.
JCP Capital is dedicated to investing in early to growth-stage companies across various sectors, including deep-tech, health-tech, and advanced manufacturing. The firm seeks to partner with startups that have the potential to transform their industries through technological advancements. Their investment strategy includes check sizes ranging from $1 million to $60 million, allowing them to engage with a diverse range of companies.
The firm is particularly focused on sectors such as artificial intelligence, biotechnology, healthcare, fintech, industrial technology, and robotics. JCP Capital aims to support startups transitioning from lab or prototype stages to scaled markets, emphasizing the importance of industrialization in their investment thesis. The firm values partnerships that can enhance the growth and market entry of innovative technologies.
JCP Capital's portfolio includes notable companies that reflect its focus on deep technology and health-tech. Key investments include:
Additionally, JCP Capital has been involved in investments in companies like 硅芯科技 and 优睿谱, further solidifying its presence in the deep-tech and health-tech sectors. Notably, the firm was part of the successful IPO of 博瑞医药 in 2019, showcasing its capability to identify and support high-potential companies.
David Cong / 丛远华 — Founder and Managing Partner. He holds degrees in computer science from Peking University and has completed executive education at Stanford. David has a history of founding multiple companies with successful exits prior to establishing JCP Capital.
Ronald Hu / 胡学龙 — Managing Partner. Ronald has a PhD in semiconductor physics from Case Western Reserve University and has worked in various roles at TCL, including founder/GM of TCL smart-home and VP of TCL Communications.
马雪芳 — Co-founder and Managing Partner. She is recognized as an early practitioner in Chinese venture investing, with over 20 technology company investments and nearly 10 IPO/acquisition outcomes.
苏战 — Managing Partner. He has a background in computer science and has worked with multinational tech firms across Singapore, Hong Kong, and Silicon Valley, focusing on AI education and big data.
于晓燕 / Sasha Yu — Managing Partner. Sasha specializes in oncology immunotherapy and NGS sequencing, with a strong focus on health-tech investments.
Freya Zhou — Director. Freya has been with JCP Capital since April 2018, bringing prior marketing and agency experience to her role.
In April 2023, JCP Capital participated in a CNY 100 million Series A round for 广东跃昉科技有限公司, marking a significant investment in the deep-tech sector. Earlier, in March 2022, the firm was involved in a CNY 100 million Series A round for 深圳市十沣科技有限公司, which focuses on advanced manufacturing and cloud simulation.
In June 2021, JCP Capital invested in a CNY 150 million Series C round for 数说故事 DataStory, further expanding its portfolio in the technology sector. The firm also played a role in the RMB 50 million B+ round for 智昌科技集团股份有限公司 in 2021, showcasing its commitment to supporting high-potential startups.
What are JCP Capital's investment criteria?
JCP Capital focuses on early to growth-stage investments in sectors such as deep-tech, health-tech, and advanced manufacturing. They look for startups with high growth potential and innovative solutions that can transform their industries.
How can founders pitch to JCP Capital?
Founders interested in pitching to JCP Capital should prepare a detailed presentation that outlines their business model, market potential, and technological innovations. While specific application channels are not disclosed, a warm introduction through industry connections may enhance the chances of engagement.
What makes JCP Capital different from other investors?
JCP Capital distinguishes itself through its focus on industrializing deep technologies and health-tech solutions. The firm's management team has extensive experience in entrepreneurship and international investment, providing valuable insights and support to portfolio companies.
What is the geographic scope of JCP Capital's investments?
JCP Capital primarily focuses on the Greater Bay Area in China but maintains a global perspective, particularly in deep-tech and health-tech sectors. Their team has experience in Silicon Valley, which enhances their international investment capabilities.
What is the typical check size for JCP Capital?
JCP Capital typically invests between $1 million and $60 million in its portfolio companies, allowing for flexibility in supporting startups at various stages of growth.
What kind of support do portfolio companies receive?
JCP Capital provides strategic capital and value-added services to its portfolio companies, leveraging its extensive networks and expertise in entrepreneurship and industrialization to facilitate growth and market entry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.